SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

SAN

83.43

+1.19%↑

MRK1

118.9

+2.06%↑

SHL.DE

43.61

+1.49%↑

ARGX

756.8

-1.66%↓

FRE

47.89

-0.06%↓

Search

Almirall SA

Chiusa

SettoreSettore sanitario

13.2 1.23

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

12.86

Massimo

13.22

Metriche Chiave

By Trading Economics

Entrata

4.1M

13M

Vendite

-14M

260M

P/E

Media del settore

60.7

77.671

EPS

0.1

Margine di Profitto

4.811

Dipendenti

2,026

EBITDA

-23M

54M

Raccomandazioni

By TipRanks

Raccomandazioni

Acquista

Previsioni per 12 mesi

+6.6% upside

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-80M

2.6B

Apertura precedente

11.97

Chiusura precedente

13.2

Notizie sul Sentiment di mercato

By Acuity

58%

42%

335 / 374 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

Almirall SA Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

10 dic 2025, 22:02 UTC

Utili

Synopsys Sees Strong 2026 as Ansys Acquisition Boosts 4Q Revenue

10 dic 2025, 21:46 UTC

Utili

Adobe Expects Double-Digit Recurring Revenue Growth Next Year

10 dic 2025, 23:52 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Its Offer Is 'Superior' -- Barrons.com

10 dic 2025, 23:43 UTC

Discorsi di Mercato

Nikkei May Rise After Fed Rate Cut -- Market Talk

10 dic 2025, 23:36 UTC

Discorsi di Mercato

Gold Consolidates as Traders Digest FOMC Decision -- Market Talk

10 dic 2025, 23:20 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- 2nd Update

10 dic 2025, 23:15 UTC

Utili

Synopsys Targets Double-Digit Growth Following Ansys Acquisition -- Interview

10 dic 2025, 22:59 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Adobe Expects Semrush Deal to Bring in New Users -- Market Talk

10 dic 2025, 22:45 UTC

Discorsi di Mercato

Coca-Cola's New CEO Pick Looks A Lot Like The Last One -- Market Talk

10 dic 2025, 22:40 UTC

Utili

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:06 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 22:06 UTC

Utili

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 22:02 UTC

Utili

Synopsys Stock Rises on Earnings Beat, Higher Guidance -- Barrons.com

10 dic 2025, 22:00 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- Update

10 dic 2025, 21:53 UTC

Utili

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:50 UTC

Acquisizioni, Fusioni, Takeovers

Investors Bet That a Higher Bid for Warner Is Coming -- Update

10 dic 2025, 21:50 UTC

Discorsi di Mercato
Utili
Acquisizioni, Fusioni, Takeovers

Financial Services Roundup: Market Talk

10 dic 2025, 21:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

10 dic 2025, 21:50 UTC

Discorsi di Mercato

Auto & Transport Roundup: Market Talk

10 dic 2025, 21:45 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Sends Letter to Warner Bros. Shareholders Saying Their Offer Is 'Superior' -- Barrons.com

10 dic 2025, 21:33 UTC

Utili

Oracle Reports $16.1 Billion in Revenue, Narrowly Missing Forecasts -- WSJ

10 dic 2025, 21:32 UTC

Utili

Oracle Reports Mixed Earnings. The Stock Is Falling. -- Barrons.com

10 dic 2025, 21:28 UTC

Acquisizioni, Fusioni, Takeovers

Sverica Capital Management Announces Sale of Coastal Cloud Holdings to Tata Consultancy Services for $700M

10 dic 2025, 21:25 UTC

Utili

Adobe Earnings Show 'Rapid Adoption' of AI Tools. The Stock Is Up. -- Barrons.com

10 dic 2025, 21:18 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance: Company Has Air Tight Financing to Deliver on Warner Bros. Offer >PSKY

10 dic 2025, 21:16 UTC

Utili

Oracle Reports Mixed Earnings. The Stock is Falling. -- Barrons.com

10 dic 2025, 21:15 UTC

Acquisizioni, Fusioni, Takeovers

Paramount Skydance: Public Offer for Warner Bros. Delivers Superior Value, Faster, More Certain Path to Completion

10 dic 2025, 21:15 UTC

Utili

Oracle: 'Sold Ampere Because We No Longer Think It Is Strategic for Us to Continue Designing, Manufacturing and Using Our Own Chips in Our Cloud Datacenters' >ORCL

10 dic 2025, 21:14 UTC

Utili

Oracle 2Q Non-GAAP Operating Income Was $6.7 B >ORCL

10 dic 2025, 21:14 UTC

Utili

Oracle 2Q GAAP Operating Income Was $4.7 B >ORCL

Confronto tra pari

Modifica del prezzo

Almirall SA Previsione

Obiettivo di Prezzo

By TipRanks

6.6% in crescita

Previsioni per 12 mesi

Media 13.9 EUR  6.6%

Alto 14.5 EUR

Basso 13.3 EUR

Basato su 2 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Almirall SA - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Acquista

2 ratings

2

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

9.76 / 10.2Supporto e resistenza

A breve termine

Bearish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Strong Bullish Evidence

Sentiment

By Acuity

335 / 374 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove ribassiste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Almirall SA

Almirall, S.A., a biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising actinic keratosis, atopic dermatitis, alopecia areata, skin cancer, psoriasis, onychomycosis, vitiligo, hidradenitis suppurativa, oncodermatology, acne, orphan indications, and rare skin diseases, as well as for alimentary tract and metabolism; antiinfectives for systemic use; cardiovascular, musculo-skeletal, respiratory, and nervous system; dermatologicals; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. It has a multi-target alliance with Etherna to research and develop new mRNA-based therapies for severe skin diseases, including non-melanoma skin cancer. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
help-icon Live chat